David Greenblum, MD
Psychiatry · Kensington, MDNPI 1467462713
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,330 of the $58,451 with a category attached, or 65.6%. Johnson & Johnson accounts for 91.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $13,583 and has fallen 87.6% since, to $1,679 in 2025. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $171.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$53K
- Neurocrine Biosciences, Inc.$782
- Teva Pharmaceuticals USA, Inc.$705
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$618
- Otsuka America Pharmaceutical, Inc.$592
- AbbVie$589
- plus $2K from 13 others
What the payments were for
- Consulting fees$8,83515%
- Speaking & faculty fees$38,33066%
- Travel & lodging$4,0617%
- Food & beverage$7,17812%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 108 | $53,211 |
| Neurocrine Biosciences, Inc. | 24 | $782 |
| Teva Pharmaceuticals USA, Inc. | 30 | $705 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $618 |
| Otsuka America Pharmaceutical, Inc. | 32 | $592 |
| AbbVie | 24 | $589 |
| E.r. Squibb & Sons, L.L.C. | 19 | $417 |
| Supernus Pharmaceuticals, Inc. | 18 | $325 |
| Alkermes, Inc. | 14 | $322 |
| Corium, LLC | 17 | $320 |
| Indivior Inc. | 7 | $170 |
| Braeburn Inc. | 5 | $128 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Sunovion Pharmaceuticals Inc. | 2 | $54 |
| Tempus AI, Inc | 1 | $28 |
| Almatica Pharma LLC | 1 | $17 |
| Neos Therapeutics, LP | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$51,528
- INVEGA TRINZA$50,738
- INGREZZA$122
- COBENFY$114
- Austedo XR$103
- QELBREE$101
How this compares
$58,451 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $143,372 |
| Invega SustennaPaliperidone Palmitate | 23 | $68,291 |
| Abilify MaintenaAripiprazole | 25 | $53,340 |
| CaplytaLumateperone Tosylate | 29 | $52,903 |
| VraylarCariprazine Hcl | 14 | $22,352 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 112 | $15,785 |
| Lurasidone Hcl | 20 | $2,470 |
| Clozapine | 60 | $2,293 |
| Aripiprazole | 83 | $2,165 |
| Quetiapine Fumarate | 161 | $1,834 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $1,150 |
| Clonazepam | 99 | $1,112 |
| Olanzapine | 40 | $960 |
| Gabapentin | 60 | $826 |
| Risperidone | 60 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $705 | $143,37218 claims |
| Johnson & JohnsonInvega Sustenna | $53,211 | $68,29123 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $592 | $53,34025 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $618 | $52,90329 claims |
| AbbVieVraylar | $589 | $22,35214 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $681118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Kensington
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.